Drug Trial Radar · NCT05631704
A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity
Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Dec 2, 2022
Primary completion
Jul 27, 2023
Study completion Jul 27, 2023
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants.
Conditions
- HIV Infections
Interventions
VH4524184Drug
VH4524184 will be administered.
MidazolamDrug
Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with serious adverse events (SAE) and non-serious adverse events (non-SAE)Time frame: Up to 4 weeks
- Part 2: Number of participants with SAE and non-SAETime frame: Up to 6.5 weeks
- Part 3: Number of participants with SAE and non-SAETime frame: Up to 6.5 weeks
- Part 1: Number of participants with adverse events based on severityTime frame: Up to 4 weeks
- Part 2: Number of participants with adverse events by severityTime frame: Up to 6.5 weeks
- Part 3: Number of participants with adverse events based on severityTime frame: Up to 6.5 weeks
- Part 1: Percentage of participants who discontinue treatment due to adverse events (AE)Time frame: Up to 4 weeks
- Part 2: Percentage of participants who discontinue treatment due to AETime frame: Up to 6.5 weeks
- Part 3: Percentage of participants who discontinue treatment due to AETime frame: Up to 6.5 weeks
- Part 1: Change from Baseline in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) (International units per liter)Time frame: Baseline (Day 1) and up to 4 weeks
- Part 2: Change from Baseline in AST, ALT and ALP (International units per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 3: Change from Baseline in AST, ALT and ALP (International units per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 1: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)Time frame: Baseline (Day 1) and up to 4 weeks
- Part 2: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 3: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 1: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)Time frame: Baseline (Day 1) and up to 4 weeks
- Part 2: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 3: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 1: Change from Baseline in International normalized ratio (INR) (Ratio)Time frame: Baseline (Day 1) and up to 4 weeks
- Part 2: Change from Baseline in INR (Ratio)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 3: Change from Baseline in INR (Ratio)Time frame: Baseline (Day 1) and up to 6.5 weeks
- Part 1: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INRTime frame: Baseline (Day 1) and up to 4 weeks
- Part 2: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INRTime frame: Baseline (Day 1) and up to 6.5 weeks
- Part 3: Number of participant with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INRTime frame: Baseline (Day 1) and up to 6.5 weeks
- Part 1: Area under the plasma-concentration time curve from zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) following dosing of VH4524184Time frame: Up to 4 weeks
- Part 2: Area under the plasma concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tau]) following dosing of VH4524184Time frame: Up to 6.5 weeks
- Part 1: Maximum observed plasma drug concentration (Cmax) following dosing of VH4524184Time frame: Up to 4 weeks
- Part 2: Cmax following dosing of VH4524184Time frame: Up to 6.5 weeks
- Part 1: Time to maximum observed plasma drug concentration (tmax) following dosing of VH4524184Time frame: Up to 4 weeks
- Part 2: Tmax following dosing of VH4524184Time frame: Up to 6.5 weeks
- Part 1: Apparent terminal half-life (t1/2) following dosing of VH4524184Time frame: Up to 4 weeks
- Part 2: T1/2 following dosing of VH4524184Time frame: Up to 6.5 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.